RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a
specialty pharmaceutical company focused on the commercialization
of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%,
for the treatment of acquired blepharoptosis, or droopy or
low-lying eyelids, in adults, today announced financial results and
business highlights for the three months ended March 31, 2023.
“RVL is off to a great start on the year. Our
one-of-a-kind product continues to exhibit year-over-year growth as
we leverage our cost base for improved efficiency. Our
multi-channel strategy is delivering favorable results. In
fact, monthly pharmacy prescriptions reached an all-time high
during the first quarter of 2023, despite the absence of
personal promotional support. Additionally, momentum in aesthetics
continued, with growth in the percentage of reorders and in new
account openings during the quarter. We believe we have barely
scratched the surface of the potential for this amazing product,”
stated Brian Markison, Chief Executive Officer of RVL.
“We believe the July rollout of Elevate, our
next-generation e-commerce portal, will be a powerful step that
will broaden our reach, improve the customer experience and
facilitate enhanced access to UPNEEQ – all while providing us with
data and analytics to further inform our marketing initiatives,”
continued Markison.
“The social proof behind UPNEEQ continues to
build, as evidenced by being selected the winner as ‘Best Eye Drop
for Drooping Lids’ in the NewBeauty 13th Annual Beauty Awards. This
is our second consecutive win, following our award last year from
NewBeauty for the ‘Best Innovation,’” concluded Markison.
First Quarter 2023 Financial
Highlights
- UPNEEQ
net product sales were $8.8 million, an increase of $2.9 million,
or 49%, over the first quarter of 2022.
-
Approximately 4,800 cumulative unique medical aesthetics practices
had placed orders for UPNEEQ at quarter end, an increase of 12%
from the end of 2022.
-
Approximately 19,900 cumulative unique pharmacy-paid prescribers at
quarter end, an increase of 8% compared to the end of 2022.
- At
quarter end, the optometry and ophthalmology customer base
accounted for 68% and 32%, respectively, of its total unique eye
care prescriber base.
- Net loss was
$(11.6) million, compared to a net loss of $(6.8) million in the
prior year period. Adjusted EBITDA1 loss was $(8.7) million,
compared to an Adjusted EBITDA loss of $(18.9) million in the first
quarter of 2022.
- At March 31,
2023, the Company had cash and cash equivalents of $32.6 million
and senior secured indebtedness with aggregate principal maturities
of $70.7 million.
First Quarter 2023 Financial Results
Net product sales, relating entirely to sales of
UPNEEQ, increased by $2.9 million to $8.8 million for the three
months ended March 31, 2023, as compared to $5.9 million for
the three months ended March 31, 2022, primarily due to a
year-over-year increase in sales volume reflecting expanded
commercialization into the medical aesthetics market in February
2022 and into telemedicine in the second half of 2022.
Royalty and licensing revenues were $15.5
million in the three months ended March 31, 2022, reflecting
milestone revenues recognized under our agreement with Santen.
There was no royalty and licensing revenue in the three months
ended March 31, 2023.
Total revenues decreased by $12.6 million to
$8.8 million in the three months ended March 31, 2023, as compared
to $21.4 million in the three months ended March 31, 2022,
primarily due to the absence of licensing revenue from Santen
during 2023, partially offset by a year-over-year increase in net
product sales. For the three months ended March 31, 2023, one
customer accounted for 21% of the Company’s total revenues.
Total cost of goods sold increased by $0.2
million to $2.3 million in the three months ended March 31, 2023,
as compared to $2.1 million in the three months ended March 31,
2022. The year-over-year increase in cost of goods sold was
primarily driven by $0.3 million in higher product costs for UPNEEQ
due to higher sales volume.
Gross profit percentage decreased to 74% in the
three months ended March 31, 2023, as compared to 90% in the 2022
period, largely due to unique licensing revenue from Santen
recognized during the 2022 period. Excluding licensing revenues,
gross profit percentage from net product sales was 74% and 64% in
the 2023 and 2022 periods, respectively, reflecting lower royalty
expense, inclusive of contingent earn out obligations, and improved
overhead absorption driven by higher volumes.
Selling, general and administrative expenses
decreased by $7.6 million to $16.2 million in the three months
ended March 31, 2023, as compared to $23.8 million in the three
months ended March 31, 2022. The year-over-year decrease in
selling, general and administrative expenses was primarily driven
by (i) $5.6 million in lower net compensation and training costs
primarily relating to the absence of an eye care salesforce in the
2023 period, (ii) $0.9 million in lower legal, insurance and other
professional fees, (iii) $0.5 million in lower share-based
compensation, and (iv) $0.4 million in lower marketing expenses for
UPNEEQ.
Research and development expenses decreased by
$0.3 million to $0.6 million in the three months ended March 31,
2023, as compared to $0.9 million in the three months ended March
31, 2022. The year-over-year decrease in research and development
expenses primarily reflects $0.2 million in lower share-based
compensation expense.
Total other non-operating activities were a
source of income of $1.3 million and $1.5 million in the three
months ended March 31, 2023, and 2022, respectively. Non-operating
income in each of the 2023 and 2022 periods was primarily
attributable to the receipt of an aggregate of $5.0 million in cash
from Alora related to contingent milestone payments earned in
connection with the sale of our legacy business in 2021.
Non-operating income in the 2023 and 2022 periods was partially
offset by aggregate losses recognized from the change in fair value
of the Company’s debt and warrant liability.
Net loss increased by $(4.8) million to an
$(11.6) million loss in the three months ended March 31, 2023, as
compared to a $(6.8) million loss in the three months ended March
31, 2022. Adjusted EBITDA loss decreased by $10.2 million to an
$(8.7) million loss in the three months ended March 31, 2023, as
compared to an $(18.9) million loss in the three months ended March
31, 2022.
Liquidity
At March 31, 2023, the Company had cash and cash
equivalents of $32.6 million and senior secured indebtedness with
aggregate principal maturities of $70.7 million, which are
reflected on its balance sheet at fair value of $56.3 million.
Presentation of Non-GAAP Financial Measures
In addition to our results determined in
accordance with accounting principles generally accepted in the
United States of America (“GAAP”) throughout this press release, we
also present Adjusted EBITDA loss, which is a non-GAAP financial
measurement. Adjusted EBITDA loss represents earnings before
interest, taxes, depreciation and amortization (or “EBITDA”)
adjusted for (i) non-operating income or expense and (ii) the
impact of certain non-cash, non-recurring or other items that are
included in net loss and EBITDA that we do not consider indicative
of our ongoing operating performance. In particular, our
measurement of Adjusted EBITDA loss excludes the following from
EBITDA: licensing-related revenues, net of transaction costs;
divestiture-related contingent milestone payments, net of fees;
changes in the fair value of our debt and interest expense and
warrant liability recognized through earnings; gains or losses on
the sale of product rights; impairments of intangible assets; asset
disposal charges; debt financing costs; share-based compensation
expense; severance expenses; foreign currency translation; legal
settlements and expenses and other expenses.
We use Adjusted EBITDA loss for business
planning purposes, in assessing our performance and in measuring
our performance relative to that of our competitors. We also
believe that Adjusted EBITDA loss provides investors with useful
information to understand our operating results and analyze
financial and business trends on a period-to-period basis. Adjusted
EBITDA loss has important limitations as an analytical tool,
however, and you should not consider it in isolation or as a
substitute for analysis of our results as reported under GAAP.
Adjusted EBITDA loss is not intended to replace, and should not be
considered superior to, the presentation of our financial results
in accordance with GAAP. Our definition of Adjusted EBITDA loss may
differ from similar measures reported by other companies and may
not be comparable to other similarly titled measures. Adjusted
EBITDA loss is reconciled from net loss, the most comparable GAAP
financial measure, in the attached table “RVL Pharmaceuticals plc -
GAAP to Non-GAAP Reconciliations” at the end of this press
release.
Forward-Looking Statements
This press release includes statements that
express the Company’s opinions, expectations, beliefs, plans,
objectives, assumptions or projections regarding future events or
future results and therefore are, or may be deemed to be,
“forward-looking statements.” The Company’s actual results may vary
significantly from the results anticipated in these forward-looking
statements, which can generally be identified by the use of
forward-looking terminology, including the terms “believes,”
“expects,” “may,” “will,” “should,” “seeks,” “projects,”
“approximately,” “intends,” “plans,” “targets,” “estimates” or
“anticipates,” or, in each case, their negatives or other
variations or comparable terminology. These forward-looking
statements include all matters that are not historical facts. They
include statements regarding the Company’s intentions, beliefs or
current expectations concerning, among other things, its results of
operations, financial condition, liquidity, prospects, financial
guidance, growth plan, strategies, trends and other events,
particularly relating to sales of UPNEEQ, U.S. Food and Drug
Administration (“FDA”) and other regulatory applications, approvals
and actions, the rollout of Elevate, our next generation e-commerce
portal and the expansion into telemedicine, the continuation of
historical trends, our ability to manage costs and service our debt
and the sufficiency of our cash balances and cash generated from
operating and financing activities for future liquidity and capital
resource needs. By their nature, forward-looking statements involve
risks and uncertainties because they relate to events and depend on
circumstances that may or may not occur in the future. We may not
achieve the plans, intentions or expectations disclosed in our
forward-looking statements, and you should not place significant
reliance on our forward-looking statements. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements we make.
Important factors that could cause actual results and events to
differ materially from those indicated in the forward-looking
statements include the following: UPNEEQ’s ability to reach market
acceptance by clinicians and patients; our ability to successfully
commercialize UPNEEQ; our customers’ willingness to pay the price
we charge for UPNEEQ; the results of our marketing and sales
expenditures; our dependence on third-party suppliers and
distributors for UPNEEQ; UPNEEQ’s ability to produce its intended
effects; failures of or delays in clinical trials or other delays
in obtaining regulatory approval or commencing product sales for
new products; the impact of legal proceedings; and other risks and
uncertainties more fully described in the “Risk Factors” section of
our Annual Report on Form 10-K filed on March 20, 2023, and other
filings that the Company makes with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
time of this press release and we do not undertake to publicly
update or revise them, whether as a result of new information,
future events or otherwise, except as required by law.
Conference Call
As previously announced, RVL management will
host its first quarter 2023 financial results conference call as
follows:
Date: |
|
Thursday, May
11, 2023 |
Time: |
|
8:30 a.m. ET |
Toll free (U.S.): |
|
800-579-2543 |
International: |
|
785-424-1789 |
Webcast (live and replay): |
|
ir.rvlpharma.com under the “Investors & News” section |
A replay of the conference call will be
available for one week after the call's completion by dialing
800-938-0996 (U.S.) or 402-220-1540 (International) and entering
conference call ID RVLQ123. The webcast will be archived for one
year at the aforementioned URL.
IMPORTANT SAFETY INFORMATION
INDICATION
UPNEEQ® (oxymetazoline hydrochloride ophthalmic
solution), 0.1% is indicated for the treatment of acquired
blepharoptosis in adults.
WARNINGS AND PRECAUTIONS
- Ptosis may be associated with neurologic or orbital diseases
such as stroke and/or cerebral aneurysm, Horner syndrome,
myasthenia gravis, external ophthalmoplegia, orbital infection and
orbital masses. Consideration should be given to these conditions
in the presence of ptosis with decreased levator muscle function
and/or other neurologic signs.
- Alpha-adrenergic agonists as a class may impact blood pressure.
Advise UPNEEQ patients with cardiovascular disease, orthostatic
hypotension, and/or uncontrolled hypertension or hypotension to
seek medical care if their condition worsens.
- Use UPNEEQ with caution in patients with cerebral or coronary
insufficiency or Sjögren’s syndrome. Advise patients to seek
medical care if signs and symptoms of potentiation of vascular
insufficiency develop.
- UPNEEQ may increase the risk of angle closure glaucoma in
patients with untreated narrow-angle glaucoma. Advise patients to
seek immediate medical care if signs and symptoms of acute
narrow-angle glaucoma develop.
-
Patients should not touch the tip of the single patient-use
container to their eye or to any surface, in order to avoid eye
injury or contamination of the solution.
ADVERSE REACTIONS
Adverse reactions that occurred in 1-5% of
subjects treated with UPNEEQ were punctate keratitis, conjunctival
hyperemia, dry eye, blurred vision, instillation site pain, eye
irritation and headache.
DRUG INTERACTIONS
- Alpha-adrenergic agonists, as a class, may impact blood
pressure. Caution in using drugs such as betablockers,
anti-hypertensives, and/or cardiac glycosides is advised. Caution
should also be exercised in patients receiving alpha adrenergic
receptor antagonists such as in the treatment of cardiovascular
disease, or benign prostatic hypertrophy.
- Caution is advised in patients taking monoamine oxidase
inhibitors which can affect the metabolism and uptake of
circulating amines.
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty
pharmaceutical company focused on the commercialization of UPNEEQ®
(oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the
treatment of acquired blepharoptosis, or low-lying eyelid, in
adults. UPNEEQ is the first non-surgical treatment option approved
by the FDA for acquired blepharoptosis.Investor and Media
Relations for RVL Pharmaceuticals plc Lisa M.
WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
________________________________1 Adjusted
EBITDA is a non-GAAP financial measurement, see “Presentation of
Non-GAAP Financial Measures.”
-Financial Tables Follow-
RVL Pharmaceuticals plc |
|
|
|
|
|
Unaudited Condensed Consolidated Balance
Sheets |
|
|
|
|
|
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2023 |
|
December 31, 2022 |
Assets |
|
|
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
$ |
32,640 |
|
|
$ |
44,543 |
|
Accounts receivable and other receivables |
|
1,879 |
|
|
|
3,031 |
|
Inventories, net |
|
213 |
|
|
|
784 |
|
Prepaid expenses and other current assets |
|
3,620 |
|
|
|
8,617 |
|
Total current assets |
|
38,352 |
|
|
|
56,975 |
|
Property, plant and equipment, net |
|
2,487 |
|
|
|
1,276 |
|
Operating lease assets |
|
522 |
|
|
|
512 |
|
Indefinite-lived intangible assets |
|
13,900 |
|
|
|
13,900 |
|
Goodwill |
|
55,847 |
|
|
|
55,847 |
|
Total assets |
$ |
111,108 |
|
|
$ |
128,510 |
|
|
|
|
|
|
|
Liabilities and Shareholders' Equity |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Trade accounts payable |
$ |
2,630 |
|
|
$ |
2,407 |
|
Accrued liabilities |
|
9,268 |
|
|
|
15,395 |
|
Current portion of debt ($3,261 measured at fair value and
representing $3,533 of aggregate unpaid principal at March 31,
2023) |
|
4,150 |
|
|
|
1,432 |
|
Current portion of obligations under finance leases |
|
11 |
|
|
|
10 |
|
Current portion of lease liability |
|
306 |
|
|
|
435 |
|
Income taxes payable - current portion |
|
43 |
|
|
|
44 |
|
Total current liabilities |
|
16,408 |
|
|
|
19,723 |
|
Long-term debt (measured at fair value and representing $67,133 and
$75,000 of aggregate unpaid principal at March 31, 2023 and
December 31, 2022, respectively) |
|
53,039 |
|
|
|
55,500 |
|
Warrant liability |
|
1,274 |
|
|
|
1,951 |
|
Long-term portion of obligation under finance leases |
|
15 |
|
|
|
18 |
|
Long-term portion of lease liability |
|
229 |
|
|
|
94 |
|
Income taxes payable - long term portion |
|
71 |
|
|
|
70 |
|
Deferred taxes |
|
72 |
|
|
|
61 |
|
Total liabilities |
|
71,108 |
|
|
|
77,417 |
|
Shareholders' equity: |
|
|
|
|
|
Ordinary shares |
|
993 |
|
|
|
992 |
|
Additional paid in capital |
|
619,841 |
|
|
|
619,323 |
|
Accumulated deficit |
|
(580,834 |
) |
|
|
(569,222 |
) |
Total shareholders' equity |
|
40,000 |
|
|
|
51,093 |
|
Total liabilities and shareholders' equity |
$ |
111,108 |
|
|
$ |
128,510 |
|
|
|
|
|
|
|
RVL Pharmaceuticals plc |
|
|
|
|
|
Unaudited Condensed Consolidated Statements of Operations
and Comprehensive Loss |
(in thousands, except share and per share data) |
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
|
Net product sales |
$ |
8,832 |
|
|
$ |
5,944 |
|
Royalty and licensing revenue |
|
— |
|
|
|
15,500 |
|
Total revenues |
|
8,832 |
|
|
|
21,444 |
|
Cost of goods sold |
|
2,299 |
|
|
|
2,144 |
|
Gross profit |
|
6,533 |
|
|
|
19,300 |
|
Selling, general and administrative expenses |
|
16,198 |
|
|
|
23,834 |
|
Research and development expenses |
|
626 |
|
|
|
862 |
|
Total operating expenses |
|
16,824 |
|
|
|
24,696 |
|
Operating loss |
|
(10,291 |
) |
|
|
(5,396 |
) |
Interest expense and amortization of debt discount |
|
26 |
|
|
|
985 |
|
Change in fair value of debt and interest expense |
|
7,349 |
|
|
|
1,044 |
|
Change in fair value of warrants |
|
(677 |
) |
|
|
4,508 |
|
Other non-operating income, net |
|
(5,435 |
) |
|
|
(5,037 |
) |
Total other non-operating income |
|
1,263 |
|
|
|
1,500 |
|
Loss before income taxes |
|
(11,554 |
) |
|
|
(6,896 |
) |
Income tax expense (benefit) |
|
58 |
|
|
|
(75 |
) |
Net loss |
$ |
(11,612 |
) |
|
$ |
(6,821 |
) |
Change in fair value of debt due to change in credit risk, net of
tax |
|
— |
|
|
|
(1,700 |
) |
Comprehensive loss |
$ |
(11,612 |
) |
|
$ |
(8,521 |
) |
Loss per ordinary share: |
|
|
|
|
|
Basic and diluted |
$ |
(0.12 |
) |
|
$ |
(0.08 |
) |
Weighted average ordinary shares outstanding: |
|
|
|
|
|
Basic and diluted |
|
99,321,304 |
|
|
|
83,489,900 |
|
|
|
|
|
|
|
RVL Pharmaceuticals plc |
|
|
|
|
|
Unaudited Condensed Consolidated Statements of Cash
Flows |
|
|
|
|
|
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2023 |
|
2022 |
Cash Flows from Operating Activities: |
|
|
|
|
|
Net loss |
$ |
(11,612 |
) |
|
$ |
(6,821 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
|
Depreciation and amortization |
|
93 |
|
|
|
89 |
|
Share compensation |
|
499 |
|
|
|
1,209 |
|
Change in fair value of debt |
|
5,134 |
|
|
|
(400 |
) |
Change in fair value of warrants |
|
(677 |
) |
|
|
4,508 |
|
Deferred income tax benefit |
|
11 |
|
|
|
9 |
|
Gain on sale of fixed and leased assets |
|
(79 |
) |
|
|
(37 |
) |
Amortization of deferred financing and loan origination fees |
|
— |
|
|
|
967 |
|
Change in operating assets and liabilities: |
|
|
|
|
|
Accounts receivable and other receivables |
|
1,152 |
|
|
|
(15,439 |
) |
Inventories, net |
|
571 |
|
|
|
— |
|
Prepaid expenses and other current and non-current assets |
|
4,998 |
|
|
|
420 |
|
Trade accounts payable |
|
224 |
|
|
|
955 |
|
Accrued and other current liabilities |
|
(6,132 |
) |
|
|
1,264 |
|
Net cash used in operating activities |
|
(5,818 |
) |
|
|
(13,276 |
) |
Cash Flows from Investing Activities: |
|
|
|
|
|
Proceeds from sale of fixed and leased assets |
|
79 |
|
|
|
37 |
|
Purchases of property, plant and equipment |
|
(1,304 |
) |
|
|
(27 |
) |
Net cash (used in) provided by investing activities |
|
(1,225 |
) |
|
|
10 |
|
Cash Flows from Financing Activities: |
|
|
|
|
|
Payments on finance lease obligations |
|
(2 |
) |
|
|
(2 |
) |
Payments on insurance financing loan |
|
(544 |
) |
|
|
(897 |
) |
Payments for taxes related to net share settlement of share-based
awards |
|
(72 |
) |
|
|
(57 |
) |
Proceeds from issuance of ordinary shares under the ESP Plan |
|
92 |
|
|
|
119 |
|
Debt repayments |
|
(4,334 |
) |
|
|
— |
|
Net cash used in financing activities |
|
(4,860 |
) |
|
|
(837 |
) |
Net change in cash and cash equivalents |
|
(11,903 |
) |
|
|
(14,103 |
) |
Cash and cash equivalents, beginning of period |
|
44,543 |
|
|
|
40,444 |
|
Cash and cash equivalents, end of period |
$ |
32,640 |
|
|
$ |
26,341 |
|
|
|
|
|
|
|
RVL Pharmaceuticals plc |
|
GAAP to Non-GAAP Reconciliations |
|
|
|
|
|
Adjusted EBITDA (Unaudited) |
|
|
|
|
|
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2023 |
|
2022 |
|
|
|
|
|
|
Net loss |
$ |
(11,612 |
) |
|
$ |
(6,821 |
) |
Interest expense and amortization of debt discount |
|
26 |
|
|
|
985 |
|
Income tax expense (benefit) |
|
58 |
|
|
|
(75 |
) |
Depreciation and amortization expense |
|
93 |
|
|
|
89 |
|
|
|
|
|
|
|
EBITDA |
|
(11,435 |
) |
|
|
(5,822 |
) |
|
|
|
|
|
|
Licensing-related revenues, net of transaction costs(1) |
|
— |
|
|
|
(15,000 |
) |
Divestiture-related contingent milestone payments, excluding
fees(2) |
|
(5,000 |
) |
|
|
(5,000 |
) |
Debt financing costs(3) |
|
575 |
|
|
|
150 |
|
Change in fair value of debt and interest expense(4) |
|
7,349 |
|
|
|
1,044 |
|
Change in fair value of warrants(4) |
|
(677 |
) |
|
|
4,508 |
|
Share-based compensation expense |
|
499 |
|
|
|
1,209 |
|
Foreign currency translation |
|
34 |
|
|
|
14 |
|
Adjusted EBITDA Loss |
$ |
(8,655 |
) |
|
$ |
(18,897 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
(1) - 2022 includes $15,500 in licensing revenue recognized in
connection with an amendment of our License Agreement with Santen,
effective March 31, 2022, net of a $500 transaction fee expense
classified in selling, general and administrative expenses. |
(2) - Relates to contingent gains related to milestone payments
earned subsequent to the sale of our legacy business to Alora
Pharmaceuticals. |
(3) - 2023 relates to $575 in mandatory debt repayment fees,
classified in selling, general and administrative expenses,
incurred as a result of our receipt of a contingent milestone
payment. 2022 relates to $150 in consent fees, classified in
selling, general and administrative expenses, incurred with our
lendor upon the issuance of waivers of mandatory repayments of debt
following receipt of a contingent milestone payment. |
(4) - Our senior secured notes issued under our Note Purchase
Agreement, a material component of long-term debt, and our warrant
liabilities, a material component of total liabilities have each
been measured and carried at fair value since their issuance in
October 2021. Changes in the fair value of debt and warrants are
accounted for at fair value, inclusive of related accrued interest
expense in respect of debt, and are presented as periodic gains or
losses in our consolidated statements of operations and
comprehensive loss. |
|
|
|
|
|
|
Grafico Azioni RVL Pharmaceuticals (NASDAQ:RVLP)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni RVL Pharmaceuticals (NASDAQ:RVLP)
Storico
Da Lug 2023 a Lug 2024